KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $1.7 billion.

  • Moderna's Total Current Liabilities fell 23.63% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 billion, marking a year-over-year decrease of 23.63%. This contributed to the annual value of $2.2 billion for FY2024, which is 26.83% down from last year.
  • Moderna's Total Current Liabilities amounted to $1.7 billion in Q3 2025, which was up 6.93% from $1.6 billion recorded in Q2 2025.
  • In the past 5 years, Moderna's Total Current Liabilities registered a high of $10.0 billion during Q3 2021, and its lowest value of $1.6 billion during Q2 2025.
  • In the last 3 years, Moderna's Total Current Liabilities had a median value of $2.4 billion in 2024 and averaged $2.5 billion.
  • In the last 5 years, Moderna's Total Current Liabilities surged by 6,172.01% in 2021 and then plummeted by 62.12% in 2023.
  • Over the past 5 years, Moderna's Total Current Liabilities (Quarterly) stood at $9.1 billion in 2021, then slumped by 46.07% to $4.9 billion in 2022, then crashed by 38.76% to $3.0 billion in 2023, then decreased by 26.83% to $2.2 billion in 2024, then fell by 23.63% to $1.7 billion in 2025.
  • Its last three reported values are $1.7 billion in Q3 2025, $1.6 billion for Q2 2025, and $1.6 billion during Q1 2025.